查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1849801

最後填充醫藥品受託製造市場:2035年前的產業趨勢和全球預測 - 各最後填充服務形式，FDF，API滴定率，一次用包裝容器，各地區，主要企業

Fill Finish Pharmaceutical Contract Manufacturing Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Fill Finish Service Offered, FDF, API Potency, Primary Packaging Container, Geographical Regions and Leading Players
出版日期: | 出版商: Roots Analysis | 英文 340 Pages | 商品交期: 最快1-2個工作天內

價格

全球最終灌裝藥品合約生產市場預計將從目前的 75 億美元成長至 2035 年的 121 億美元，預測期內複合年增長率 (CAGR) 為 4.8%。

最終灌裝藥品合約生產市場

市場區隔將市場機會分為以下幾個部分：

最終灌裝服務類型

  • 無菌填充
  • BFS(成型同時填充)
  • 末端殺菌

FDF類型

  • 非專利FDF
  • 原廠藥FDF

API滴定率

  • 低活性API
  • 高活性API

一次用包裝容器類型

  • 安瓿
  • 濾芯
  • 預填充式注射器
  • 管瓶
  • 其他

事業規模

  • 臨床
  • 商業

企業規模

  • 中小企業
  • 大企業/超大企業

主要地區

  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·北非

最終灌裝合約生產市場成長與趨勢

目前小分子藥物約佔市場總量的近90%的治療藥物研發管線。研究表明，每年核准的新藥中約有60%是小分子藥物。這一趨勢是由該領域的快速成長所驅動的，而快速成長又源於對高效、個人化療法的日益增長的需求。此外，小分子藥物也面臨許多挑戰，尤其是在其生產過程中涉及的無菌填充環節。無菌灌裝是藥品生產的關鍵步驟。在此階段保持無菌狀態對於患者安全以及確保產品品質和療效至關重要。此外，使用小分子藥物的新製劑需要專門的工具和專業知識，這會增加生產成本。因此，許多藥物研發商傾向於將最終灌裝工序外包給合約服務提供者。

由於對專業知識和高效生產製程的需求，不斷擴展的小分子藥物研發管線及其日益複雜的特性，正在推動製藥業對專業最終灌裝生產服務的需求。

最終灌裝藥品合約生產市場關鍵洞察

本報告深入分析了最終灌裝藥品合約生產市場的現狀，並指出了該行業的潛在成長機會。主要發現包括：

  • 目前，近390家機構提供最終灌裝藥品合約生產服務，其中大多數合約生產商提供無菌灌裝服務。
Fill Finish Pharmaceutical Contract Manufacturing Market-IMG1
  • 西林瓶（63%）已成為應用最廣泛的初級包裝形式。近85%的公司具備灌裝液體製劑作為最終劑型的必要能力。
  • 目前成品藥合約生產（CMO）市場格局高度分散，主要地區既有新進者，也有老牌企業。
  • 為了獲得競爭優勢，產業參與者正積極升級現有能力並增加新能力，以強化各自的產品組合。
  • 全球藥品灌裝產能分佈在世界各地的不同工廠，大型和超大型企業佔了總產能的80%。
Fill Finish Pharmaceutical Contract Manufacturing Market-IMG2
  • 預計到2035年，成品藥灌裝合約生產市場將保持穩定成長，其中終端滅菌預計將在不久的將來佔市場佔有率的大部分（超過40%）。
Fill Finish Pharmaceutical Contract Manufacturing Market-IMG3
  • 從長遠來看，安瓿瓶和西林瓶預計將推動最終灌裝藥品合約生產市場的成長，其中西林瓶細分市場預計到2035年將佔大部分市場佔有率（50%）。

最終灌裝藥品合約生產市場的主要細分市場

目前，終端滅菌細分市場在最終灌裝藥品合約生產市場中佔最大佔有率。

根據所提供的最終灌裝服務類型，該市場可細分為無菌填充、原位填充 (BFS) 和終端滅菌。 值得注意的是，終端滅菌技術預計在未來十年主導市場。這是因為終端滅菌技術能夠確保無菌性，並提高可靠性和成本效益。

通用名製劑（FDF）在最終灌裝合約生產市場中佔最大佔有率。

依FDF類型劃分，市場分為通用名製劑及原廠製劑。值得注意的是，通用名製劑預計在未來十年主導市場。這得益於其具競爭力的價格、成本效益以及合約生產商所堅持的品質標準。

目前，低效價原料藥（API）在最終灌裝合約生產市場中佔最大佔有率。

依API強度劃分，市場分為低效價API和高效價API。由於需求量大、生產要求相對簡單且整體生產成本較低，低效價API目前在最終灌裝合約生產市場中佔主導地位。

預計在預測期內，預灌封注射器市場將以較高的複合年增長率成長。

依初級包裝類型劃分，市場可分為安瓿、藥筒、預灌封注射器、小瓶和其他容器。值得注意的是，安瓿目前在最終灌裝藥品合約生產市場中佔較大佔有率。

按業務規模劃分，預計在預測期內，商業規模將主導最終灌裝藥品合約生產市場。

依業務規模劃分，市場可分為臨床規模及商業規模。值得注意的是，目前商業規模小分子藥物灌裝服務產生的收入在最終灌裝藥品合約生產市場中佔最大佔有率。

大型和超大型服務提供者在最終灌裝藥品合約生產市場中佔最大佔有率。

依公司規模劃分，市場分為中小企業及大型及超大型企業。值得注意的是，未來十年，大型和超大型服務提供者很可能主導最終灌裝藥品合約生產市場。這得歸功於他們專業且技能嫻熟的員工隊伍、創新的填充/包裝設施以及強大的監管能力。

歐洲將佔最大的市場佔有率。

依地區劃分，市場分為北美、歐洲、亞太、拉丁美洲、中東和非洲以及世界其他地區。雖然歐洲目前佔大部分市場佔有率，但預計世界其他地區的市場將以更高的複合年增長率成長。

進入最終灌裝藥品合約生產市場的公司範例

  • Alcami
  • Amanta Healthcare
  • Aurigene Pharmaceutical Services
  • Batterjee Pharma
  • Burrard Pharmaceuticals
  • Curida
  • Eriochem
  • Fresenius Kabi
  • GlaxoSmithKline
  • Nextar Chempharma Solutions
  • Pfizer CentreOne
  • Plastikon Healthcare
  • Procaps
  • Recipharm
  • ROMMELAG CMO
  • Sharp
  • Sypharma
  • Teva Pharmaceuticals
  • WuXi AppTec

最終灌裝藥品合約生產市場研究報告

  • 市場規模和機會分析：本報告提供詳細的市場規模估算本報告對小分子藥物最終灌裝合約製藥市場進行了全面評估，重點關注以下關鍵細分市場：[A] 提供的最終灌裝服務類型，[B] 成品劑型，[C] 原料藥濃度，[D] 初級包裝容器類型，[B] 成品劑型，[C] 原料藥濃度，[D] 初級包裝容器類型，[E] 業務規模，[E] 業務規模。
  • 市場概況：本報告對參與最終灌裝合約製藥生產的公司進行了全面評估，考慮了以下各項參數：[A] 成立年份，[B] 公司規模（基於員工人數），[C] 總部所在地，[D] 生產設施所在地，[E] 業務規模，[F] 提供的最終灌裝服務類型，[D] 生產設施所在地，[E] 成品，[F] 提供的最終
  • 競爭分析：本報告深入分析了小分子藥物最終灌裝合約製藥生產商的競爭格局，並考察了公司實力、產品組合實力和產品組合多樣性等因素。
  • 公司簡介：本報告提供北美、歐洲、亞太及其他地區主要最終灌裝合約製藥企業的簡介，重點關注[A]公司概況、[B]財務資訊（如有）、[C]服務組合、[D]近期發展以及[E]未來展望。
  • 產能分析：本報告提供全球小分子藥物年度最終灌裝產能的估算。各種包裝容器（安瓿、卡式、注射器和西林瓶）的可用產能按[A]公司規模和[B]主要地區進行劃分。
  • 案例研究1：本報告包含一個案例研究，探討了在無菌最終灌裝製程中使用機器人/自動化設備的優勢。此外，還列出了提供適用於製藥操作的機器人的設備製造商。
  • 案例研究2：本報告包含一個案例研究，重點在於包裝在無菌最終填充製程中的作用。此外，還列出了提供即用型組件的供應商。
  • 成長推動因素和阻礙因素：本報告分析了影響市場成長的各種因素，包括推動因素、阻礙因素、市場推動因素和挑戰。

目錄

第1章 序文

第2章 調查手法

第3章 市場動態

  • 章概要
  • 預測調查手法
  • 市場評估組成架構
  • 預測工具和技巧
  • 重要的考慮事項
  • 主要的市場區隔
  • 堅牢的品管
  • 限制事項

第4章 經濟以及其他的計劃特有的考慮事項

第5章 摘要整理

第6章 簡介

  • 章概要
  • 低分子化合物的最後填充服務的簡介
    • 無菌填充
    • 末端殺菌
    • BFS(成型同時填充)技術
  • 低分子相關業務的外包的必要性
  • 低分子化合物產業的契約製造商所扮演的角色
  • 最後填充服務供應商選擇時應該考慮的重點
  • 最後填充服務的外包的優點
  • 最後填充業務的外包的風險與課題
  • 未來展望

第7章 市場形勢

  • 章概要
  • 低分子最後填充服務供應商:市場形勢

第8章 企業簡介北美的服務供應商

  • 章概要
  • 北美低分子最後填充服務供應商
    • Alcami
    • Pfizer CentreOne
    • Sharp Services
  • 其他的企業
    • Burrard Pharmaceuticals
    • Plastikon Healthcare

第9章 企業簡介:歐洲的服務供應商

  • 章概要
  • 歐洲低分子最後填充服務供應商
    • Fresenius Kabi
    • GlaxoSmithKline
    • Recipharm
  • 其他的企業
    • Curida
    • ROMMELAG CMO

第10章 企業簡介:亞太地區的服務供應商

  • 章概要
  • 亞太地區低分子最後填充服務供應商
    • Aurigene Pharmaceutical Services
    • Sypharma
    • WuXi AppTec
  • 其他的企業
    • Amanta Healthcare

第11章 企業簡介:其他地區的服務供應商

  • 章概要
  • 其他地區的低分子最後填充服務供應商
    • Eriochem
    • Teva Pharmaceutical Industries
  • 其他的企業
    • Batterjee Pharma
    • Procaps

第12章 企業競爭力分析

第13章 容量分析

第14章 案例研究:填充/最後潤飾工作的機器人系統

第15章 案例研究:無菌最後填充用馬上能使用的包裝零件

第16章 市場影響分析:促進因素，阻礙因素，機會，課題

第17章 全球最後填充醫藥品受託製造市場

第18章 最後填充醫藥品受託製造市場(各提供最後填充服務形式)

第19章 最後填充醫藥品受託製造市場(各FDF類型)

第20章 最後填充醫藥品受託製造市場(API效力)

第21章 最後填充醫藥品受託製造市場(一次用包裝容器各類型)

第22章 最後填充醫藥品受託製造市場(各產業規模)

第23章 最後填充醫藥品受託製造市場(不同企業規模)

第24章 最後填充醫藥品受託製造市場(各地區)

第25章 最後填充醫藥品受託製造市場(各主要企業)

第26章 結論

第27章 執行洞察

第28章 附錄I:表資料

第29章 附錄II:企業及組織一覽

Product Code: RA100231

Fill Finish Pharmaceutical Contract Manufacturing Market: Overview

As per Roots Analysis, the global fill finish pharmaceutical contract manufacturing market is estimated to grow from USD 7.5 billion in the current year to USD 12.1 billion by 2035, at a CAGR of 4.8% during the forecast period, till 2035.

Fill Finish Pharmaceutical Contract Manufacturing Market

The market opportunity has been distributed across the following segments:

Type of Fill Finish Service Offered

  • Aseptic Filling
  • Blow-Fill-Seal
  • Terminal Sterilization

Type of FDF

  • Generic FDF
  • Originator FDF

API Potency

  • Low Potent API
  • High Potent API

Type of Primary Packaging Container

  • Ampoules
  • Cartridges
  • Prefilled Syringe
  • Vials
  • Other Containers

Scale of Operation

  • Clinical
  • Commercial

Company Size

  • Small and Mid-sized Companies
  • Large / Very Large Companies

Key Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and North Africa

Fill Finish Pharmaceutical Contract Manufacturing Market: Growth and Trends

Currently, small molecule drugs constitute nearly 90% of the therapeutic pipeline. Research suggests that about 60% of the new drugs approved each year are small molecules. This trend stems from the rapid growth in this field, driven by the increasing demand for effective and personalized treatments. In addition, small molecules present various challenges, especially in the sterile fill-finish process involved in their production. The sterile fill-finish stage is a critical step in pharmaceutical manufacturing. It is important to maintain aseptic conditions during this phase for patient safety and to ensure the product's quality and effectiveness. Further, new formulations using small molecules need specialized tools and expertise, which can increase production costs. As a result, many drug developers prefer outsourcing their fill-finish operations to contract service providers.

Driven by the need for specialized knowledge and efficient production processes, the expanding pipeline and rising complexity of small molecule drugs have increased the demand for specialized fill-finish manufacturing services in the pharmaceutical sector.

Fill Finish Pharmaceutical Contract Manufacturing Market: Key Insights

The report delves into the current state of the fill finish pharmaceutical contract manufacturing market and identifies potential growth opportunities within the industry. Some key findings from the report include:

  • Presently, close to 390 organizations offer fill finish pharmaceutical contract manufacturing services; of these, majority of the contract manufacturing organizations offer aseptic filling services.
Fill Finish Pharmaceutical Contract Manufacturing Market - IMG1
  • Vials (63%) have emerged as the most adopted primary packaging container format; close to 85% of the players have the required capabilities to fill finish liquid formulations as the finished dosage form.
  • The current market landscape of fill finish pharmaceutical CMOs is highly fragmented, featuring the presence of both new entrants and established players across key geographical regions.
  • In pursuit of obtaining a competitive edge, industry stakeholders are actively upgrading their existing capabilities and adding new competencies in order to enhance their respective product portfolios.
  • The global pharmaceutical fill finish capacity is well distributed across different facilities worldwide; notably, large and very large players account for 80% of the total capacity.
Fill Finish Pharmaceutical Contract Manufacturing Market - IMG2
  • The fill finish pharmaceutical contract manufacturing market is anticipated to grow at a steady rate, till 2035; terminal sterilization is expected to capture the majority share (over 40%) of the market in foreseeable future.
Fill Finish Pharmaceutical Contract Manufacturing Market - IMG3
  • In the long term, ampoules and vials packaging formats are likely to drive the growth of fill finish pharmaceutical contract manufacturing market; vials segment is expected to capture the majority share (~50%) by 2035.

Fill Finish Pharmaceutical Contract Manufacturing Market: Key Segments

Currently, Terminal Sterilization Segment Occupies the Largest Share of the Fill Finish Pharmaceutical Contract Manufacturing Market

Based on the type of fill finish service offered, the market is segmented into aseptic filling, blow-fill-seal and terminal sterilization. It is worth highlighting that the terminal sterilization segment is likely to dominate the market in the coming decade. This can be attributed to the fact that terminal sterilization offers sterility assurance, making it more reliable and cost-effective.

Generic FDF Segment Holds Maximum Share of the Fill Finish Pharmaceutical Contract Manufacturing Market

Based on the type of FDF, the market is segmented into generic FDF and originator FDF. It is worth highlighting that the generic FDF segment is likely to dominate the market in the coming decade. This is a result of competitive pricing, cost effectiveness and quality standards maintained by contract manufacturers.

Currently, Low Potent API Segment Occupies the Largest Share of the Fill Finish Pharmaceutical Contract Manufacturing Market

Based on the type of API by potency, the market is segmented into low potent API and high potent API. Owing to their higher demand, less complex manufacturing requirements and lower overall production costs, the current fill finish pharmaceutical contract manufacturing market is dominated by low potent API.

Prefilled Syringes Segment is Likely to Grow at a Higher CAGR During the Forecast Period

Based on the type of primary packaging container, the market is segmented into ampoules, cartridges, prefilled syringe, vials and other containers. It is worth highlighting that, at present, the ampoules segment holds the larger share of the fill finish pharmaceutical contract manufacturing market.

By Scale of Operation, Commercial Scale is Likely to Dominate the Fill Finish Pharmaceutical Contract Manufacturing Market During the Forecast Period

Based on the scale of operation, the market is segmented into clinical and commercial scale. It is worth highlighting that, at present, revenues generated from commercial scale small molecules fill finish services hold maximum share in the fill finish pharmaceutical contract manufacturing market.

Large / Very Large Service Providers Accounts for the Largest Share for the Fill Finish Pharmaceutical Contract Manufacturing Market

Based on the company size, the market is segmented into small and mid-sized companies and large / very large companies. It is worth highlighting that large / very large service providers are likely to dominate the fill finish pharmaceutical contract manufacturing market in the coming decade. This can be attributed to the fact that these companies have dedicated and skilled personnel, innovative fill / finish facilities and robust regulatory capabilities.

Europe Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and rest of the world. Currently, Europe captures the majority of the market share; however the market in rest of the world is expected to grow at a higher CAGR.

Example Players in the Fill Finish Pharmaceutical Contract Manufacturing Market

  • Alcami
  • Amanta Healthcare
  • Aurigene Pharmaceutical Services
  • Batterjee Pharma
  • Burrard Pharmaceuticals
  • Curida
  • Eriochem
  • Fresenius Kabi
  • GlaxoSmithKline
  • Nextar Chempharma Solutions
  • Pfizer CentreOne
  • Plastikon Healthcare
  • Procaps
  • Recipharm
  • ROMMELAG CMO
  • Sharp
  • Sypharma
  • Teva Pharmaceuticals
  • WuXi AppTec

Fill Finish Pharmaceutical Contract Manufacturing Market: Research Coverage

  • Market Sizing and Opportunity Analysis: The report features a detailed market size estimation for fill finish pharmaceutical contract manufacturing market (for small molecules), focusing on key market segments, including [A] type of fill finish service offered, [B] type of FDF, [C] API potency, [D] type of primary packaging container, [E] scale of operation, [F] company size and [G] geographical regions.
  • Market Landscape: The report presents comprehensive evaluation of companies involved in fill finish pharmaceutical contract manufacturing, considering various parameters, such as [A] year of establishment, [B] company size (based on number of employees), [C] location of headquarters, [D] location of manufacturing facility, [E] scale of operation, [F] type of fill finish service offered, [G] type of finishing service offered [H] type of packaging format, [I] type of finished dosage form, [J] degree of automation.
  • Company Competitiveness Analysis: The report highlights a detailed competitive analysis of fill finish pharmaceutical contract manufacturers (for small molecules), examining factors, such as company strength, portfolio strength and portfolio diversity.
  • Company Profiles: The report features and in-depth profiles of key fill finish pharmaceutical contract manufacturers based in North America, Europe, Asia-Pacific and rest of the world focusing on [A] company overviews, [B] financial information (if available), [C] service portfolio, [D] recent developments and [E] an informed future outlook.
  • Capacity Analysis: The report provides an estimation of global annual small molecules fill finish capacity. The available capacity for various packaging containers used (ampoules, cartridges, syringes and vials) has been segmented across [A] company size and [B] key geographical regions.
  • Case Study 1: The report includes a case study discussing the advantages of using robotic / automated equipment for aseptic fill finish processes. In addition, it includes a list of equipment manufacturers providing robots suitable for pharmaceutical operations.
  • Case Study 2: The report contains a case study featuring the role of ready-to-use packaging containers in aseptic fill finish operations. In addition, it provides a list of suppliers providing the ready-to-use components.
  • Growth Drivers and Restraints: The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting market growth.

Key Questions Answered in this Report

  • How many companies are currently engaged in this market?
  • Which are the leading CMOs in this market?
  • What factors are likely to influence the evolution of this market?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Additional Benefits

  • Complimentary PPT Insights Packs
  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 15% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Introduction
  • 1.2. Market Share Insights
  • 1.3. Key Market Insights
  • 1.4. Report Coverage
  • 1.5. Key Questions Answered
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
    • 2.2.1. Market Landscape and Market Trends
    • 2.2.2. Market Forecast and Opportunity Analysis
    • 2.2.3. Comparative Analysis
  • 2.3. Database Building
    • 2.3.1. Data Collection
    • 2.3.2. Data Validation
    • 2.3.3. Data Analysis
  • 2.4. Project Methodology
    • 2.4.1. Secondary Research
      • 2.4.1.1. Annual Reports
      • 2.4.1.2. Academic Research Papers
      • 2.4.1.3. Company Websites
      • 2.4.1.4. Investor Presentations
      • 2.4.1.5. Regulatory Filings
      • 2.4.1.6. White Papers
      • 2.4.1.7. Industry Publications
      • 2.4.1.8. Conferences and Seminars
      • 2.4.1.9. Government Portals
      • 2.4.1.10. Media and Press Releases
      • 2.4.1.11. Newsletters
      • 2.4.1.12. Industry Databases
      • 2.4.1.13. Roots Proprietary Databases
      • 2.4.1.14. Paid Databases and Sources
      • 2.4.1.15. Social Media Portals
      • 2.4.1.16. Other Secondary Sources
    • 2.4.2. Primary Research
      • 2.4.2.1. Types of Primary Research
        • 2.4.2.1.1. Qualitative Research
        • 2.4.2.1.2. Quantitative Research
        • 2.4.2.1.3. Hybrid Approach
      • 2.4.2.2. Advantages of Primary Research
      • 2.4.2.3. Techniques for Primary Research
        • 2.4.2.3.1. Interviews
        • 2.4.2.3.2. Surveys
        • 2.4.2.3.3. Focus Groups
        • 2.4.2.3.4. Observational Research
        • 2.4.2.3.5. Social Media Interactions
      • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
        • 2.4.2.4.1. Company Executives (CXOs)
        • 2.4.2.4.2. Board of Directors
        • 2.4.2.4.3. Company Presidents and Vice Presidents
        • 2.4.2.4.4. Research and Development Heads
        • 2.4.2.4.5. Technical Experts
        • 2.4.2.4.6. Subject Matter Experts
        • 2.4.2.4.7. Scientists
        • 2.4.2.4.8. Doctors and Other Healthcare Providers
      • 2.4.2.5. Ethics and Integrity
        • 2.4.2.5.1. Research Ethics
        • 2.4.2.5.2. Data Integrity
    • 2.4.3. Analytical Tools and Databases

3. MARKET DYNAMICS

  • 3.1. Chapter Overview
  • 3.2. Forecast Methodology
    • 3.2.1. Top-down Approach
    • 3.2.2. Bottom-up Approach
    • 3.2.3. Hybrid Approach
  • 3.3. Market Assessment Framework
    • 3.3.1. Total Addressable Market (TAM)
    • 3.3.2. Serviceable Addressable Market (SAM)
    • 3.3.3. Serviceable Obtainable Market (SOM)
    • 3.3.4. Currently Acquired Market (CAM)
  • 3.4. Forecasting Tools and Techniques
    • 3.4.1. Qualitative Forecasting
    • 3.4.2. Correlation
    • 3.4.3. Regression
    • 3.4.4. Extrapolation
    • 3.4.5. Convergence
    • 3.4.6. Sensitivity Analysis
    • 3.4.7. Scenario Planning
    • 3.4.8. Data Visualization
    • 3.4.9. Time Series Analysis
    • 3.4.10. Forecast Error Analysis
  • 3.5. Key Considerations
    • 3.5.1. Demographics
    • 3.5.2. Government Regulations
    • 3.5.3. Reimbursement Scenarios
    • 3.5.4. Market Access
    • 3.5.5. Supply Chain
    • 3.5.6. Industry Consolidation
    • 3.5.7. Pandemic / Unforeseen Disruptions Impact
  • 3.6. Key Market Segmentation
  • 3.7. Robust Quality Control
  • 3.8. Limitations

4. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 4.1. Chapter Overview
  • 4.2. Market Dynamics
    • 4.2.1. Time Period
      • 4.2.1.1. Historical Trends
      • 4.2.1.2. Current and Forecasted Estimates
    • 4.2.2. Currency Coverage
      • 4.2.2.1. Overview of Major Currencies Affecting the Market
      • 4.2.2.2. Impact of Currency Fluctuations on the Industry
    • 4.2.3. Foreign Exchange Impact
      • 4.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
      • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 4.2.4. Recession
      • 4.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
      • 4.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 4.2.5. Inflation
      • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 4.2.5.2. Potential Impact of Inflation on the Market Evolution

5. EXECUTIVE SUMMARY

6. INTRODUCTION

  • 6.1. Chapter Overview
  • 6.2. Introduction to Fill / Finish Services for Small Molecules
    • 6.2.1. Aseptic Filling
    • 6.2.2. Terminal Sterilization
    • 6.2.3. Blow-Fill-Seal Technology
  • 6.3. Need for Outsourcing Small Molecules-related Operations
  • 6.4. Role of Contract Manufacturers in the Small Molecules Industry
  • 6.5. Key Considerations while selecting a Fill / Finish Service Provider
  • 6.6. Advantages of Outsourcing Fill / Finish Services
  • 6.7. Risks and Challenges of Outsourcing Fill / Finish Operations
  • 6.8. Future Perspectives

7. MARKET LANDSCAPE

  • 7.1. Chapter Overview
  • 7.2. Small Molecules Fill / Finish Service Providers: Overall Market Landscape
    • 7.2.1. Analysis by Year of Establishment
    • 7.2.2. Analysis by Company Size
    • 7.2.3. Analysis by Location of Headquarters
    • 7.2.4. Analysis by Location of Fill / Finish Facilities
    • 7.2.5. Analysis by Scale of Operation
    • 7.2.6. Analysis by Type of Filling Service Offered
    • 7.2.7. Analysis by Type of Finishing Service Offered
    • 7.2.8. Analysis by Type of Packaging Format Used
    • 7.2.9. Analysis by Type of Finished Dosage Form
    • 7.2.10. Analysis by Degree of Automation

8. COMPANY PROFILES: SERVICE PROVIDERS IN NORTH AMERICA

  • 8.1. Chapter Overview
  • 8.2. Leading Small Molecules Fill / Finish Service Providers based in North America
    • 8.2.1. Alcami
      • 8.2.1.1. Company Overview
      • 8.2.1.2. Small Molecules Fill / Finish Service Portfolio
      • 8.2.1.3. Recent Developments and Future Outlook
    • 8.2.2. Pfizer CentreOne
      • 8.2.2.1. Company Overview
      • 8.2.2.2. Small Molecules Fill / Finish Service Portfolio
      • 8.2.2.3. Recent Developments and Future Outlook
    • 8.2.3. Sharp Services
      • 8.2.3.1. Company Overview
      • 8.2.3.2. Small Molecules Fill / Finish Service Portfolio
      • 8.2.3.3. Recent Developments and Future Outlook
  • 8.3. Other Leading Small Molecules Fill / Finish Service Providers based in North America
    • 8.3.1. Burrard Pharmaceuticals
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Small Molecules Fill / Finish Service Portfolio
    • 8.3.2. Plastikon Healthcare
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Small Molecules Fill / Finish Service Portfolio

9. COMPANY PROFILES: SERVICE PROVIDERS IN EUROPE

  • 9.1. Chapter Overview
  • 9.2. Leading Small Molecules Fill / Finish Service Providers based in Europe
    • 9.2.1. Fresenius Kabi
      • 9.2.1.1. Company Overview
      • 9.2.1.2. Financial Information
      • 9.2.1.3. Small Molecules Fill / Finish Service Portfolio
      • 9.2.1.4. Recent Developments and Future Outlook
    • 9.2.2. GlaxoSmithKline
      • 9.2.2.1. Company Overview
      • 9.2.2.2. Financial Information
      • 9.2.2.3. Small Molecules Fill / Finish Service Portfolio
      • 9.2.2.4. Recent Developments and Future Outlook
    • 9.2.3. Recipharm
      • 9.2.3.1. Company Overview
      • 9.2.3.2. Small Molecules Fill / Finish Service Portfolio
      • 9.2.3.3. Recent Developments and Future Outlook
  • 9.3. Other Leading Small Molecules Fill / Finish Service Providers based in Europe
    • 9.3.1. Curida
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Small Molecules Fill / Finish Service Portfolio
    • 9.3.2. ROMMELAG CMO
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Small Molecules Fill / Finish Service Portfolio

10. COMPANY PROFILES: SERVICE PROVIDERS IN ASIA-PACIFIC

  • 10.1. Chapter Overview
  • 10.2. Leading Small Molecules Fill / Finish Service Providers based in Asia-Pacific
    • 10.2.1. Aurigene Pharmaceutical Services
      • 10.2.1.1. Company Overview
      • 10.2.1.2. Small Molecules Fill / Finish Service Portfolio
      • 10.2.1.3. Recent Developments and Future Outlook
    • 10.2.2. Sypharma
      • 10.2.2.1. Company Overview
      • 10.2.2.2. Small Molecules Fill / Finish Service Portfolio
      • 10.2.2.3. Recent Developments and Future Outlook
    • 10.2.3. WuXi AppTec
      • 10.2.3.1. Company Overview
      • 10.2.3.2. Small Molecules Fill / Finish Service Portfolio
      • 10.2.3.3. Recent Developments and Future Outlook
  • 10.3. Other Small Molecules Fill / Finish Service Providers based in Asia-Pacific
    • 10.3.1. Amanta Healthcare
      • 10.3.1.1. Company Overview
      • 10.3.1.2. Small Molecules Fill / Finish Service Portfolio

11. COMPANY PROFILES: SERVICE PROVIDERS IN REST OF THE WORLD

  • 11.1. Chapter Overview
  • 11.2. Leading Small Molecules Fill / Finish Service Providers based in Rest of the World
    • 11.2.1. Eriochem
      • 11.2.1.1. Company Overview
      • 11.2.1.2. Small Molecules Fill / Finish Service Portfolio
      • 11.2.1.3. Recent Developments and Future Outlook
    • 11.2.2. Teva Pharmaceutical Industries
      • 11.2.2.1. Company Overview
      • 11.2.2.2. Small Molecules Fill / Finish Service Portfolio
      • 11.2.2.3. Recent Developments and Future Outlook
  • 11.3. Other Small Molecules Fill / Finish Service Providers based in Rest of the World
    • 11.3.1. Batterjee Pharma
      • 11.3.1.1. Company Overview
      • 11.3.1.2. Small Molecules Fill / Finish Service Portfolio
    • 11.3.2. Procaps
      • 11.3.2.1. Company Overview
      • 11.3.2.2. Small Molecules Fill / Finish Service Portfolio

12. COMPANY COMPETITIVENESS ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Assumptions and Key Parameters
  • 12.3. Methodology
  • 12.4. Small Molecules Fill / Finish Service Providers based in North America
  • 12.5. Small Molecules Fill / Finish Service Providers based in Europe
  • 12.6. Small Molecules Fill / Finish Service Providers based in Asia-Pacific and Rest of the World

13. CAPACITY ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Global Annual Small Molecules Fill / Finish Capacity for Ampoules (Number of Units)
    • 13.2.1. Key Assumptions and Methodology
    • 13.2.2. Analysis by Company Size
    • 13.2.3. Analysis by Geography
      • 13.2.3.1. Analysis of Small Molecules Fill / Finish Capacity for Ampoules in North America
      • 13.2.3.2. Analysis of Small Molecules Fill / Finish Capacity for Ampoules in Europe
      • 13.2.3.3. Analysis of Small Molecules Fill / Finish Capacity for Ampoules in Asia-Pacific and Rest of the World
  • 13.3. Global Annual Small Molecules Fill / Finish Capacity for Cartridges (Number of Units)
    • 13.3.1. Key Assumptions and Methodology
    • 13.3.2. Analysis by Company Size
    • 13.3.3. Analysis by Geography
      • 13.3.3.1. Analysis of Small Molecules Fill / Finish Capacity for Cartridges in North America
      • 13.3.3.2. Analysis of Small Molecules Fill / Finish Capacity for Cartridges in Europe
      • 13.3.3.3. Analysis of Small Molecules Fill / Finish Capacity for Cartridges in Asia-Pacific and Rest of the World
  • 13.4. Global Annual Small Molecules Fill / Finish Capacity for Prefilled Syringes (Number of Units)
    • 13.4.1. Key Assumptions and Methodology
    • 13.4.2. Analysis by Company Size
    • 13.4.3. Analysis by Geography
      • 13.4.3.1. Analysis of Small Molecules Fill / Finish Capacity for Prefilled Syringes in North America
      • 13.4.3.2. Analysis of Small Molecules Fill / Finish Capacity for Prefilled Syringes in Europe
      • 13.4.3.3. Analysis of Small Molecules Fill / Finish Capacity for Prefilled Syringes in Asia-Pacific and Rest of the World
  • 13.5. Global Annual Small Molecules Fill / Finish Capacity for Vials (Number of Units)
    • 13.5.1. Key Assumptions and Methodology
    • 13.5.2. Analysis by Company Size
    • 13.5.3. Analysis by Geography
      • 13.5.3.1. Analysis of Small Molecules Fill / Finish Capacity for Vials in North America
      • 13.5.3.2. Analysis of Small Molecules Fill / Finish Capacity for Vials in Europe
      • 13.5.3.3. Analysis of Small Molecules Fill / Finish Capacity for Vials in Asia-Pacific and Rest of the World

14. CASE STUDY: ROBOTIC SYSTEMS IN FILL / FINISH OPERATIONS

  • 14.1. Chapter Overview
  • 14.2. Role of Robotic Systems in Fill / Finish Operations
    • 14.2.1. Types of Robots Used
    • 14.2.2. Key Considerations for Selecting Robotic Systems
  • 14.3. Companies Providing Robots for use in the Pharmaceutical Industry
  • 14.4. Companies Providing Isolator- based Aseptic Filling Systems
  • 14.5. Small Molecules Fill / Finish Service Providers: List of Equipment Used
  • 14.6. Concluding Remarks

15. CASE STUDY: READY-TO-USE PACKAGING COMPONENTS FOR ASEPTIC FILL / FINISH

  • 15.1. Chapter Overview
  • 15.2. Role of Ready-to-Use Packaging Components in Aseptic Fill / Finish Operations
    • 15.2.1. Advantages of Ready-to-Use Packaging Components
    • 15.2.2. Disadvantages of Ready-to-Use Packaging Components
  • 15.3. Companies Providing Ready-to-Use Packaging Components
  • 15.4. Concluding Remarks

16. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

  • 16.1. Chapter Overview
  • 16.2. Market Drivers
  • 16.3. Market Restraints
  • 16.4. Market Opportunities
  • 16.5. Market Challenges
  • 16.6. Conclusion

17. GLOBAL PHARMACEUTICAL FILL / FINISH MANUFACTURING MARKET

  • 17.1. Chapter Overview
  • 17.2. Assumptions and Methodology
  • 17.3. Global Pharmaceutical Fill / Finish Manufacturing Market, till 2035
    • 17.3.1. Scenario Analysis
      • 17.3.1.1. Conservative Scenario
      • 17.3.1.2. Optimistic Scenario
  • 17.4. Key Market Segmentations

18. PHARMACEUTICAL FILL / FINISH MANUFACTURING MARKET, BY TYPE OF FILL / FINISH SERVICE OFFERED

  • 18.1. Chapter Overview
  • 18.2. Assumptions and Methodology
  • 18.3. Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Type of Fill / Finish Service Offered, 2019, Current Year and 2035
    • 18.3.1. Pharmaceutical Fill / Finish Manufacturing Market for Terminal Sterilization, till 2035
    • 18.3.2. Pharmaceutical Fill / Finish Manufacturing Market for Aseptic Filling, till 2035
    • 18.3.3. Pharmaceutical Fill / Finish Manufacturing Market for Blow-Fill-Seal, till 2035
  • 18.4. Pharmaceutical Fill / Finish Manufacturing Market, by Type of Fill / Finish Services Offered: Market Dynamics Assessment
    • 18.4.1. Penetration-Growth (P-G) Matrix
    • 18.4.2. Data Triangulation and Validation

19. PHARMACEUTICAL FILL / FINISH MANUFACTURING MARKET, BY TYPE OF FDF

  • 19.1. Chapter Overview
  • 19.2. Assumptions and Methodology
  • 19.3. Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Type of FDF, 2019, Current Year and 2035
    • 19.3.1. Pharmaceutical Fill / Finish Manufacturing Market for Generic FDF, till 2035
    • 19.3.2. Pharmaceutical Fill / Finish Manufacturing Market for Originator FDF, till 2035
  • 19.4. Pharmaceutical Fill / Finish Manufacturing Market, by Type of FDF: Market Dynamics Assessment
    • 19.4.1. Penetration-Growth (P-G) Matrix
    • 19.4.2. Data Triangulation and Validation

20. PHARMACEUTICAL FILL / FINISH MANUFACTURING MARKET, BY API POTENCY

  • 20.1. Chapter Overview
  • 20.2. Assumptions and Methodology
  • 20.3. Pharmaceutical Fill / Finish Manufacturing Market: Distribution by API Potency, 2019, Current Year and 2035
    • 20.3.1. Pharmaceutical Fill / Finish Manufacturing Market for Low Potent API, till 2035
    • 20.3.2. Pharmaceutical Fill / Finish Manufacturing Market for High Potent API, till 2035
  • 20.4. Pharmaceutical Fill / Finish Manufacturing Market, by API Potency: Market Dynamics Assessment
    • 20.4.1. Penetration-Growth (P-G) Matrix
    • 20.4.2. Data Triangulation and Validation

21. PHARMACEUTICAL FILL / FINISH MANUFACTURING MARKET, BY TYPE OF PRIMARY PACKAGING CONTAINER

  • 21.1. Chapter Overview
  • 21.2. Assumptions and Methodology
  • 21.3. Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Type of Primary Packaging Container, 2019, Current Year and 2035
    • 21.3.1. Pharmaceutical Fill / Finish Manufacturing Market for Vials, till 2035
    • 21.3.2. Pharmaceutical Fill / Finish Manufacturing Market for Ampoules, till 2035
    • 21.3.3. Pharmaceutical Fill / Finish Manufacturing Market for Prefilled Syringes, till 2035
    • 21.3.4. Pharmaceutical Fill / Finish Manufacturing Market for Cartridges, till 2035
    • 21.3.5. Pharmaceutical Fill / Finish Manufacturing Market for Other Containers, till 2035
  • 21.4. Pharmaceutical Fill / Finish Manufacturing Market, by Type of Primary Packaging Container: Market Dynamics Assessment
    • 21.4.1. Penetration-Growth (P-G) Matrix
    • 21.4.2. Data Triangulation and Validation

22. PHARMACEUTICAL FILL / FINISH MANUFACTURING MARKET, BY SCALE OF OPERATION

  • 22.1. Chapter Overview
  • 22.2. Assumptions and Methodology
  • 22.3. Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Scale of Operation, 2019, Current Year and 2035
    • 22.3.1. Pharmaceutical Fill / Finish Manufacturing Market for Clinical Scale, till 2035
    • 22.3.2. Pharmaceutical Fill / Finish Manufacturing Market for Commercial Scale, till 2035
  • 22.4. Pharmaceutical Fill / Finish Manufacturing Market, by Scale of Operation: Market Dynamics Assessment
    • 22.4.1. Penetration-Growth (P-G) Matrix
    • 22.4.2. Data Triangulation and Validation

23. PHARMACEUTICAL FILL / FINISH MANUFACTURING MARKET, BY COMPANY SIZE

  • 23.1. Chapter Overview
  • 23.2. Assumptions and Methodology
  • 23.3. Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Company Size, 2019, Current Year and 2035
    • 23.3.1. Pharmaceutical Fill / Finish Manufacturing Market for Small and Mid-sized Companies, till 2035
    • 23.3.2. Pharmaceutical Fill / Finish Manufacturing Market for Large / Very Large Companies, till 2035
  • 23.4. Pharmaceutical Fill / Finish Manufacturing Market, by Company Size: Market Dynamics Assessment
    • 23.4.1. Penetration-Growth (P-G) Matrix
    • 23.4.2. Data Triangulation and Validation

24. PHARMACEUTICAL FILL / FINISH MANUFACTURING MARKET, BY GEOGRAPHICAL REGIONS

  • 24.1. Chapter Overview
  • 24.2. Assumptions and Methodology
  • 24.3. Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Geographical Regions, 2019, Current Year and 2035
    • 24.3.1. Pharmaceutical Fill / Finish Manufacturing Market in North America, till 2035
      • 24.3.1.1. Pharmaceutical Fill / Finish Manufacturing Market in the US, till 2035
      • 24.3.1.2. Pharmaceutical Fill / Finish Manufacturing Market in Canada, till 2035
      • 24.3.1.3. Pharmaceutical Fill / Finish Manufacturing Market in Mexico, till 2035
      • 24.3.1.4. Pharmaceutical Fill / Finish Manufacturing Market in Puerto Rico, till 2035
    • 24.3.2. Pharmaceutical Fill / Finish Manufacturing Market in Europe, till 2035
      • 24.3.2.1. Pharmaceutical Fill / Finish Manufacturing Market in France, till 2035
      • 24.3.2.2. Pharmaceutical Fill / Finish Manufacturing Market in Germany, till 2035
      • 24.3.2.3. Pharmaceutical Fill / Finish Manufacturing Market in Italy, till 2035
      • 24.3.2.4. Pharmaceutical Fill / Finish Manufacturing Market in the UK, till 2035
      • 24.3.2.5. Pharmaceutical Fill / Finish Manufacturing Market in Spain, till 2035
      • 24.3.2.6. Pharmaceutical Fill / Finish Manufacturing Market in Rest of Europe, till 2035
    • 24.3.3. Pharmaceutical Fill / Finish Manufacturing Market in Asia-Pacific, till 2035
      • 24.3.3.1. Pharmaceutical Fill / Finish Manufacturing Market in India, till 2035
      • 24.3.3.2. Pharmaceutical Fill / Finish Manufacturing Market in Japan, till 2035
      • 24.3.3.3. Pharmaceutical Fill / Finish Manufacturing Market in China, till 2035
      • 24.3.3.4. Pharmaceutical Fill / Finish Manufacturing Market in Rest of Asia-Pacific, till 2035
    • 24.3.4. Pharmaceutical Fill / Finish Manufacturing Market in Middle East and North Africa, till 2035
    • 24.3.5. Pharmaceutical Fill / Finish Manufacturing Market in Latin America, till 2035
    • 24.3.6. Pharmaceutical Fill / Finish Manufacturing Market in Rest of the World, till 2035
  • 24.4. Pharmaceutical Fill / Finish Manufacturing Market, by Geographical Regions: Market Dynamics Assessment
    • 24.4.1. Penetration-Growth (P-G) Matrix
    • 24.4.2. Data Triangulation and Validation

25. PHARMACEUTICAL FILL / FINISH MANUFACTURING MARKET, BY LEADING PLAYERS

  • 25.1. Chapter Overview
  • 25.2. Leading Industry Players

26. CONCLUSION

27. EXECUTIVE INSIGHT

  • 27.1. Chapter Overview
  • 27.2. Company A
    • 27.2.1. Company Snapshot
    • 27.2.2. Interview Transcript: Senior Executive Director, Global Sales and Marketing

28. APPENDIX I: TABULATED DATA

29. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

  • Table 7.1 Small Molecules Fill / Finish Service Providers: List of Companies
  • Table 7.2 Small Molecules Fill / Finish Service Providers: Information on Scale of Operation, Type of Filling Service Offered and Type of Finishing Service Offered
  • Table 7.3 Small Molecules Fill / Finish Service Providers: Information on Type of Packaging Format Used, Type of Finished Dosage Form and Degree of Automation
  • Table 8.1 Small Molecules Fill / Finish Service Providers in North America: List of Companies Profiled
  • Table 8.2 Alcami: Company Overview
  • Table 8.3 Alcami: Small Molecules Fill / Finish Service Portfolio
  • Table 8.4 Alcami: Recent Developments and Future Outlook
  • Table 8.5 Pfizer CentreOne: Company Overview
  • Table 8.6 Pfizer CentreOne: Small Molecules Fill / Finish Service Portfolio
  • Table 8.7 Sharp Services: Company Overview
  • Table 8.8 Sharp Services: Small Molecules Fill / Finish Service Portfolio
  • Table 8.9 Sharp Services: Recent Developments and Future Outlook
  • Table 8.10 Burrard Pharmaceuticals: Company Overview
  • Table 8.11 Burrard Pharmaceuticals: Small Molecules Fill / Finish Service Portfolio
  • Table 8.12 Plastikon Healthcare: Company Overview
  • Table 8.13 Plastikon Healthcare: Small Molecules Fill / Finish Service Portfolio
  • Table 9.1 Small Molecules Fill / Finish Service Providers: List of Companies Profiled
  • Table 9.2 Fresenius Kabi: Company Overview
  • Table 9.3 Fresenius Kabi: Small Molecules Fill / Finish Service Portfolio
  • Table 9.4 Fresenius Kabi: Recent Developments and Future Outlook
  • Table 9.5 GlaxoSmithKline: Company Overview
  • Table 9.6 GlaxoSmithKline: Small Molecules Fill / Finish Service Portfolio
  • Table 9.7 GlaxoSmithKline: Recent Developments and Future Outlook
  • Table 9.8 Recipharm: Company Overview
  • Table 9.9 Recipharm: Small Molecules Fill / Finish Service Portfolio
  • Table 9.10 Recipharm: Recent Developments and Future Outlook
  • Table 9.11 Curida: Company Overview
  • Table 9.12 Curida: Small Molecules Fill / Finish Service Portfolio
  • Table 9.13 ROMMELAG CMO: Company Overview
  • Table 9.14 ROMMELAG CMO: Small Molecules Fill / Finish Service Portfolio
  • Table 10.1 Small Molecules Fill / Finish Service Providers: List of Companies Profiled
  • Table 10.2 Aurigene Pharmaceutical Services: Company Overview
  • Table 10.3 Aurigene Pharmaceutical Services: Small Molecules Fill / Finish Service Portfolio
  • Table 10.4 Aurigene Pharmaceutical Services: Recent Developments and Future Outlook
  • Table 10.5 Sypharma: Company Overview
  • Table 10.6 Sypharma: Small Molecules Fill / Finish Service Portfolio
  • Table 10.7 Sypharma: Recent Developments and Future Outlook
  • Table 10.8 WuXi AppTec: Company Overview
  • Table 10.9 WuXi AppTec: Small Molecules Fill / Finish Service Portfolio
  • Table 10.10 WuXi AppTec: Recent Developments and Future Outlook
  • Table 10.11 Amanta Healthcare: Company Overview
  • Table 10.12 Amanta Healthcare: Small Molecules Fill / Finish Service Portfolio
  • Table 11.1 Small Molecules Fill / Finish Service Providers: List of Companies Profiled
  • Table 11.2 Eriochem: Company Overview
  • Table 11.3 Eriochem: Small Molecules Fill / Finish Service Portfolio
  • Table 11.4 Teva Pharmaceutical Industries: Company Overview
  • Table 11.5 Teva Pharmaceutical Industries: Small Molecules Fill / Finish Service Portfolio
  • Table 11.6 Teva Pharmaceutical Industries: Recent Developments and Future Outlook
  • Table 11.7 Batterjee Pharma: Company Overview
  • Table 11.8 Batterjee Pharma: Small Molecules Fill / Finish Service Portfolio
  • Table 11.9 Nextar Chempharma Solutions: Company Overview
  • Table 11.10 Nextar Chempharma Solutions: Small Molecules Fill / Finish Service Portfolio
  • Table 11.11 Procaps: Company Overview
  • Table 11.12 Procaps: Small Molecules Fill / Finish Service Portfolio
  • Table 13.1 Small Molecules Fill / Finish Service Providers: Information on Total Capacity for Ampoules (Sample Data Set)
  • Table 13.2 Small Molecules Fill / Finish Service Providers: Average Capacity per Facility for Ampoules, by Company Size (Sample Dataset)
  • Table 13.3 Global Annual Small Molecules Fill / Finish Capacity for Ampoules, by Company Size (in terms of units)
  • Table 13.4 Small Molecules Fill / Finish Service Providers: Information on Total Capacity for Cartridges (Sample Data Set)
  • Table 13.5 Small Molecules Fill / Finish Service Providers: Average Capacity per Facility for Cartridges, by Company Size (Sample Dataset)
  • Table 13.6 Global Annual Small Molecules Fill / Finish Capacity for Cartridges, by Company Size (in terms of units)
  • Table 13.7 Small Molecules Fill / Finish Service Providers: Information on Total Capacity for Prefilled Syringes (Sample Data Set)
  • Table 13.8 Small Molecules Fill / Finish Service Providers: Average Capacity per Facility for Prefilled Syringes, by Company Size (Sample Dataset)
  • Table 13.9 Global Annual Small Molecules Fill / Finish Capacity for Prefilled Syringes, by Company Size (in terms of units)
  • Table 13.10 Small Molecules Fill / Finish Service Providers: Information on Total Capacity for Vials (Sample Data Set)
  • Table 13.11 Small Molecules Fill / Finish Service Providers: Average Capacity for Vials, by Company Size (Sample Dataset)
  • Table 13.12 Global Annual Small Molecules Fill / Finish Capacity for Vials: Total Capacity by Company Size (in terms of units)
  • Table 14.1 List of Companies Providing Robots for Use in Pharmaceutical Industry
  • Table 14.2 Isolator-based Aseptic Filling Systems: Information on Compatible Primary Container
  • Table 14.3 Small Molecules Fill / Finish Service Providers: Information on Fill / Finish Equipment Used
  • Table 15.1 List of Companies Providing Ready-to-Use Packaging Components
  • Table 25.1 Leading Industry Players: Based on the Annual Capacity Installed
  • Table 27.1 Bushu Pharmaceuticals: Company Overview
  • Table 28.1 Small Molecules Fill / Finish Service Providers: Distribution by Year of Establishment
  • Table 28.2 Small Molecules Fill / Finish Service Providers: Distribution by Company Size
  • Table 28.3 Small Molecules Fill / Finish Service Providers: Distribution by Location of Headquarters
  • Table 28.4 Small Molecules Fill / Finish Service Providers: Distribution by Location of Fill / Finish Facilities
  • Table 28.5 Small Molecules Fill / Finish Service Providers: Distribution by Scale of Operation
  • Table 28.6 Small Molecules Fill / Finish Service Providers: Distribution by Type of Filling Service Offered
  • Table 28.7 Small Molecules Fill / Finish Service Providers: Distribution by Type of Finishing Service Offered
  • Table 28.8 Small Molecules Fill / Finish Service Providers: Distribution by Type of Packaging Format Used
  • Table 28.9 Small Molecules Fill / Finish Service Providers: Distribution by Type of Finished Dosage Form
  • Table 28.10 Small Molecules Fill / Finish Service Providers: Distribution by Degree of Automation
  • Table 28.11 Pfizer (parent company of Pfizer CentreOne): Business Segment-wise Revenues and Consolidated Financial Details (USD Billion)
  • Table 28.12 Fresenius Kabi: Business Segment-wise Revenues and Consolidated Financial Details (EUR Billion)
  • Table 28.13 GlaxoSmithKline: Business Segment-wise Revenues and Consolidated Financial Details (EUR Billion)
  • Table 28.14 WuXi AppTec: Business Segment-wise Revenues and Consolidated Financial Details (RMB Billion)
  • Table 28.15 Global Annual Small Molecules Fill / Finish Capacity for Ampoules: Distribution by Company Size
  • Table 28.16 Global Annual Small Molecules Fill / Finish Capacity for Ampoules: Distribution by Location of Fill / Finish Facility
  • Table 28.17 Small Molecules Fill / Finish Capacity for Ampoules in North America
  • Table 28.18 Small Molecules Fill / Finish Capacity for Ampoules in Europe
  • Table 28.19 Small Molecules Fill / Finish Capacity for Ampoules in Asia-Pacific and Rest of the World
  • Table 28.20 Global Annual Small Molecules Fill / Finish Capacity for Cartridges: Distribution by Company Size
  • Table 28.21 Global Annual Small Molecules Fill / Finish Capacity for Cartridges: Distribution by Location of Fill / Finish Facility
  • Table 28.22 Small Molecules Fill / Finish Capacity for Cartridges in North America
  • Table 28.23 Small Molecules Fill / Finish Capacity for Cartridges in Europe
  • Table 28.24 Small Molecules Fill / Finish Capacity for Cartridges in Asia-Pacific and Rest of the World
  • Table 28.25 Global Annual Small Molecules Fill / Finish Capacity for Prefilled Syringes: Distribution by Company Size
  • Table 28.26 Global Annual Small Molecules Fill / Finish Capacity for Prefilled Syringes: Distribution by Location of Fill / Finish Facility
  • Table 28.27 Small Molecules Fill / Finish Capacity for Prefilled Syringes in North America
  • Table 28.28 Small Molecules Fill / Finish Capacity for Prefilled Syringes in Europe
  • Table 28.29 Small Molecules Fill / Finish Capacity for Prefilled Syringes in Asia-Pacific and Rest of the World
  • Table 28.30 Global Annual Small Molecules Fill / Finish Capacity for Vials: Distribution by Company Size
  • Table 28.31 Global Annual Small Molecules Fill / Finish Capacity for Vials: Distribution by Location of Fill / Finish Facility
  • Table 28.32 Small Molecules Fill / Finish Capacity for Vials in North America
  • Table 28.33 Small Molecules Fill / Finish Capacity for Vials in Europe
  • Table 28.34 Small Molecules Fill / Finish Capacity for Vials in Asia-Pacific and Rest of the World
  • Table 28.35 Global Pharmaceutical Fill / Finish Manufacturing Market: Conservative, Base, Optimistic Scenario, till 2035 (USD Billion)
  • Table 28.36 Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Type of Fill / Finish Service Offered, 2019, Current Year and 2035 (USD Billion)
  • Table 28.37 Pharmaceutical Fill / Finish Manufacturing Market for Terminal Sterilization, till 2035 (USD Billion)
  • Table 28.38 Pharmaceutical Fill / Finish Manufacturing Market for Aseptic Filling, till 2035 (USD Billion)
  • Table 25.39 Pharmaceutical Fill / Finish Manufacturing Market for Blow-Fill-Seal, till 2035 (USD Billion)
  • Table 28.40 Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Type of FDF, 2019, Current Year and 2035 (USD Billion)
  • Table 28.41 Pharmaceutical Fill / Finish Manufacturing Market for Originator FDF, till 2035 (USD Billion)
  • Table 28.42 Pharmaceutical Fill / Finish Manufacturing Market for Generic FDF, till 2035 (USD Billion)
  • Table 28.43 Pharmaceutical Fill / Finish Manufacturing Market: Distribution by API Potency, 2019, Current Year and 2035 (USD Billion)
  • Table 28.44 Pharmaceutical Fill / Finish Manufacturing Market for Low Potent API, till 2035 (USD Billion)
  • Table 28.45 Pharmaceutical Fill / Finish Manufacturing Market for High Potent API, till 2035 (USD Billion)
  • Table 28.46 Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Type of Primary Packaging Container, 2019, Current Year and 2035 (USD Billion)
  • Table 28.47 Pharmaceutical Fill / Finish Manufacturing Market for Vials, till 2035 (USD Billion)
  • Table 28.48 Pharmaceutical Fill / Finish Manufacturing Market for Prefilled Syringes, till 2035 (USD Billion)
  • Table 28.49 Pharmaceutical Fill / Finish Manufacturing Market for Ampoules, till 2035 (USD Billion)
  • Table 28.50 Pharmaceutical Fill / Finish Manufacturing Market for Cartridges, till 2035 (USD Billion)
  • Table 28.51 Pharmaceutical Fill / Finish Manufacturing Market for Other Containers, till 2035 (USD Billion)
  • Table 28.52 Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Scale of Operation, 2019, Current Year and 2035 (USD Billion)
  • Table 28.53 Pharmaceutical Fill / Finish Manufacturing Market for Clinical Scale, till 2035 (USD Billion)
  • Table 28.54 Pharmaceutical Fill / Finish Manufacturing Market for Commercial Scale, till 2035 (USD Billion)
  • Table 28.55 Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Company Size, 2019, Current Year and 2035 (USD Billion)
  • Table 28.56 Pharmaceutical Fill / Finish Manufacturing Market for Small and Mid-sized Companies, till 2035 (USD Billion)
  • Table 28.57 Pharmaceutical Fill / Finish Manufacturing Market for Large / Very Large Companies, till 2035 (USD Billion)
  • Table 28.58 Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Geographical Regions 2019, Current Year and 2035 (USD Billion)
  • Table 28.59 Pharmaceutical Fill / Finish Manufacturing Market in North America, till 2035 (USD Billion)
  • Table 28.60 Pharmaceutical Fill / Finish Manufacturing Market in the US, till 2035 (USD Billion)
  • Table 28.61 Pharmaceutical Fill / Finish Manufacturing Market in Canada, till 2035 (USD Billion)
  • Table 28.62 Pharmaceutical Fill / Finish Manufacturing Market in Mexico, till 2035 (USD Billion)
  • Table 28.63 Pharmaceutical Fill / Finish Manufacturing Market in Puerto Rico, till 2035 (USD Billion)
  • Table 28.64 Pharmaceutical Fill / Finish Manufacturing Market in Europe, till 2035 (USD Billion)
  • Table 28.65 Pharmaceutical Fill / Finish Manufacturing Market in France, till 2035 (USD Billion)
  • Table 28.66 Pharmaceutical Fill / Finish Manufacturing Market in Germany, till 2035 (USD Billion)
  • Table 28.67 Pharmaceutical Fill / Finish Manufacturing Market in Italy, till 2035 (USD Billion)
  • Table 28.68 Pharmaceutical Fill / Finish Manufacturing Market in the UK, till 2035 (USD Billion)
  • Table 28.69 Pharmaceutical Fill / Finish Manufacturing Market in Spain, till 2035 (USD Billion)
  • Table 28.70 Pharmaceutical Fill / Finish Manufacturing Market in Rest of Europe, till 2035 (USD Billion)
  • Table 28.71 Pharmaceutical Fill / Finish Manufacturing Market in Asia-Pacific, till 2035 (USD Billion)
  • Table 28.72 Pharmaceutical Fill / Finish Manufacturing Market in India, till 2035 (USD Billion)
  • Table 28.73 Pharmaceutical Fill / Finish Manufacturing Market in Japan, till 2035 (USD Billion)
  • Table 28.74 Pharmaceutical Fill / Finish Manufacturing Market in China, till 2035 (USD Billion)
  • Table 28.75 Pharmaceutical Fill / Finish Manufacturing Market in Rest of Asia-Pacific, till 2035 (USD Billion)
  • Table 28.76 Pharmaceutical Fill / Finish Manufacturing Market in Middle East and North Africa, till 2035 (USD Billion)
  • Table 28.77 Pharmaceutical Fill / Finish Manufacturing Market in Latin America, till 2035 (USD Billion)
  • Table 28.78 Pharmaceutical Fill / Finish Manufacturing Market in Rest of the World, till 2035 (USD Billion)

List of Figures

  • Figure 2.1 Research Methodology: Project Methodology
  • Figure 2.2 Research Methodology: Data Sources for Secondary Research
  • Figure 3.1 Market Dynamics: Forecast Methodology
  • Figure 3.2 Market Dynamics: Key Market Segmentation
  • Figure 3.3 Market Dynamics: Robust Quality Control
  • Figure 4.1 Lessons Learnt from Past Recessions
  • Figure 5.1 Executive Summary: Market Landscape
  • Figure 5.2 Executive Summary: Market Forecast and Opportunity Analysis
  • Figure 6.1 Steps involved in Fill / Finish of Small Molecules
  • Figure 6.2 Blow-Fill-Seal Process
  • Figure 6.3 Key Considerations for Selecting a CMO Partner
  • Figure 6.4 Risks and Challenges of Outsourcing Fill / Finish Operations
  • Figure 7.1 Small Molecules Fill / Finish Service Providers: Distribution by Year of Establishment
  • Figure 7.2 Small Molecules Fill / Finish Service Providers: Distribution by Company Size
  • Figure 7.3 Small Molecules Fill / Finish Service Providers: Distribution by Location of Headquarters
  • Figure 7.4 Small Molecules Fill / Finish Service Providers: Distribution by Location of Fill / Finish Facilities
  • Figure 7.5 Small Molecules Fill / Finish Service Providers: Distribution by Scale of Operation
  • Figure 7.6 Small Molecules Fill / Finish Service Providers: Distribution by Type of Filling Service Offered
  • Figure 7.7 Small Molecules Fill / Finish Service Providers: Distribution by Type of Finishing Service Offered
  • Figure 7.8 Small Molecules Fill / Finish Service Providers: Analysis by Type of Packaging Format Used
  • Figure 7.9 Small Molecules Fill / Finish Service Providers: Distribution by Type of Finished Dosage Form
  • Figure 7.10 Small Molecules Fill / Finish Service Providers: Distribution by Degree of Automation
  • Figure 8.1 Pfizer (parent company of Pfizer CentreOne): Business Segment-wise Revenues and Consolidated Financial Details (USD Billion)
  • Figure 9.1 Fresenius: Business Segment-wise Revenues and Consolidated Financial Details (EUR Billion)
  • Figure 9.2 GlaxoSmithKline: Business Segment-wise Revenues and Consolidated Financial Details (EUR Billion)
  • Figure 10.1 WuXi AppTec: Business Segment-wise Revenues and Consolidated Financial Details (RMB Billion)
  • Figure 12.1 Company Competitiveness Analysis: Small Molecules Fill / Finish Service Providers based in North America
  • Figure 12.2 Company Competitiveness Analysis: Small Molecules Fill / Finish Service Providers based in Europe
  • Figure 12.3 Company Competitiveness Analysis: Small Molecules Fill / Finish Service Providers based in Asia-Pacific and Rest of the World
  • Figure 13.1 Global Annual Small Molecules Fill / Finish Capacity for Ampoules: Distribution by Company Size
  • Figure 13.2 Global Annual Small Molecules Fill / Finish Capacity for Ampoules: Distribution by Location of Fill / Finish Facility
  • Figure 13.3 Small Molecules Fill / Finish Capacity for Ampoules in North America
  • Figure 13.4 Small Molecules Fill / Finish Capacity for Ampoules in Europe
  • Figure 13.5 Small Molecules Fill / Finish Capacity for Ampoules in Asia-Pacific and Rest of the World
  • Figure 13.6 Global Annual Small Molecules Fill / Finish Capacity for Cartridges: Distribution by Company Size
  • Figure 13.7 Global Annual Small Molecules Fill / Finish Capacity for Cartridges: Distribution by Location of Fill / Finish Facility
  • Figure 13.8 Small Molecules Fill / Finish Capacity for Cartridges in North America
  • Figure 13.9 Small Molecules Fill / Finish Capacity for Cartridges in Europe
  • Figure 13.10 Small Molecules Fill / Finish Capacity for Cartridges in Asia-Pacific and Rest of the World
  • Figure 13.11 Global Annual Small Molecules Fill / Finish Capacity for Prefilled Syringes: Distribution by Company Size
  • Figure 13.12 Global Annual Small Molecules Fill / Finish Capacity for Prefilled Syringes: Distribution by Location of Fill / Finish Facility
  • Figure 13.13 Small Molecules Fill / Finish Capacity for Prefilled Syringes in North America
  • Figure 13.14 Small Molecules Fill / Finish Capacity for Prefilled Syringes in Europe
  • Figure 13.15 Small Molecules Fill / Finish Capacity for Prefilled Syringes in Asia-Pacific and Rest of the World
  • Figure 13.16 Global Annual Small Molecules Fill / Finish Capacity for Vials: Distribution by Company Size
  • Figure 13.17 Global Annual Small Molecules Fill / Finish Capacity for Vials: Distribution by Location of Fill / Finish Facility
  • Figure 13.18 Small Molecules Fill / Finish Capacity for Vials in North America
  • Figure 13.19 Small Molecules Fill / Finish Capacity for Vials in Europe
  • Figure 13.20 Small Molecules Fill / Finish Capacity for Vials in Asia-Pacific and Rest of the World
  • Figure 14.1 Key Considerations for Selecting a Robotic Systems
  • Figure 14.2 Advantages of Using Robotic Systems
  • Figure 15.1 Key Drivers of Ready-to- Use Components
  • Figure 16.1 Pharmaceutical Fill / Finish Manufacturing: Market Drivers
  • Figure 16.2 Pharmaceutical Fill / Finish Manufacturing: Market Restraints
  • Figure 16.3 Pharmaceutical Fill / Finish Manufacturing: Market Opportunities
  • Figure 16.4 Pharmaceutical Fill / Finish Manufacturing: Market Challenges
  • Figure 17.1 Global Pharmaceutical Fill / Finish Manufacturing Market, till 2035 (USD Billion)
  • Figure 17.2 Global Pharmaceutical Fill / Finish Manufacturing Market, till 2035: Conservative Scenario (USD Billion)
  • Figure 17.3 Global Pharmaceutical Fill / Finish Manufacturing Market, till 2035: Optimistic Scenario (USD Billion)
  • Figure 18.1 Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Type of Fill / Finish Service Offered, 2019, Current Year and 2035
  • Figure 18.2 Pharmaceutical Fill / Finish Manufacturing Market for Terminal Sterilization, till 2035 (USD Billion)
  • Figure 18.3 Pharmaceutical Fill / Finish Manufacturing Market for Aseptic Filling, till 2035 (USD Billion)
  • Figure 18.4 Pharmaceutical Fill / Finish Manufacturing Market for Blow-Fill-Seal, till 2035 (USD Billion)
  • Figure 18.5 Penetration-Growth (P-G) Matrix: Type of Fill / Finish Service Offered
  • Figure 19.1 Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Type of FDF, 2019, Current Year and 2035
  • Figure 19.2 Pharmaceutical Fill / Finish Manufacturing Market for Originator FDF, till 2035 (USD Billion)
  • Figure 19.3 Pharmaceutical Fill / Finish Manufacturing Market for Generic FDF, till 2035 (USD Billion)
  • Figure 19.4 Penetration-Growth (P-G) Matrix: Type of FDF
  • Figure 20.1 Pharmaceutical Fill / Finish Manufacturing Market: Distribution by API Potency, 2019, Current Year and 2035
  • Figure 20.2 Pharmaceutical Fill / Finish Manufacturing Market for Low Potent API, till 2035 (USD Billion)
  • Figure 20.3 Pharmaceutical Fill / Finish Manufacturing Market for High Potent API, till 2035 (USD Billion)
  • Figure 20.4 Penetration-Growth (P-G) Matrix: API Potency
  • Figure 21.1 Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Type of Primary Packaging Container, 2019, Current Year and 2035
  • Figure 21.2 Pharmaceutical Fill / Finish Manufacturing Market for Vials, till 2035 (USD Billion)
  • Figure 21.3 Pharmaceutical Fill / Finish Manufacturing Market for Prefilled Syringes, till 2035 (USD Billion)
  • Figure 21.4 Pharmaceutical Fill / Finish Manufacturing Market for Ampoules, till 2035 (USD Billion)
  • Figure 21.5 Pharmaceutical Fill / Finish Manufacturing Market for Cartridges, till 2035 (USD Billion)
  • Figure 21.6 Pharmaceutical Fill / Finish Manufacturing Market for Other Containers, till 2035 (USD Billion)
  • Figure 21.7 Penetration-Growth (P-G) Matrix: Type of Primary Packaging Container
  • Figure 22.1 Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Scale of Operation, 2019, Current Year and 2035
  • Figure 22.2 Pharmaceutical Fill / Finish Manufacturing Market for Clinical Scale, till 2035 (USD Billion)
  • Figure 22.3 Pharmaceutical Fill / Finish Manufacturing Market for Commercial Scale, till 2035 (USD Billion)
  • Figure 22.4 Penetration-Growth (P-G) Matrix: Scale of Operation
  • Figure 23.1 Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Company Size, 2019, Current Year and 2035
  • Figure 23.2 Pharmaceutical Fill / Finish Manufacturing Market for Small and Mid-sized Companies, till 2035 (USD Billion)
  • Figure 23.3 Pharmaceutical Fill / Finish Manufacturing Market for Large / Very Large Companies, till 2035 (USD Billion)
  • Figure 23.4 Penetration-Growth (P-G) Matrix: Company Size
  • Figure 24.1 Pharmaceutical Fill / Finish Manufacturing Market: Distribution by Geographical Regions 2019, Current Year and 2035
  • Figure 24.2 Pharmaceutical Fill / Finish Manufacturing Market in North America, till 2035 (USD Billion)
  • Figure 24.3 Pharmaceutical Fill / Finish Manufacturing Market in the US, till 2035 (USD Billion)
  • Figure 24.4 Pharmaceutical Fill / Finish Manufacturing Market in Canada, till 2035 (USD Billion)
  • Figure 24.5 Pharmaceutical Fill / Finish Manufacturing Market in Mexico, till 2035 (USD Billion)
  • Figure 24.6 Pharmaceutical Fill / Finish Manufacturing Market in Puerto Rico, till 2035 (USD Billion)
  • Figure 24.7 Pharmaceutical Fill / Finish Manufacturing Market in Europe, till 2035 (USD Billion)
  • Figure 24.8 Pharmaceutical Fill / Finish Manufacturing Market in France, till 2035 (USD Billion)
  • Figure 24.9 Pharmaceutical Fill / Finish Manufacturing Market in Germany, till 2035 (USD Billion)
  • Figure 24.10 Pharmaceutical Fill / Finish Manufacturing Market in Italy, till 2035 (USD Billion)
  • Figure 24.11 Pharmaceutical Fill / Finish Manufacturing Market in the UK, till 2035 (USD Billion)
  • Figure 24.12 Pharmaceutical Fill / Finish Manufacturing Market in Spain, till 2035 (USD Billion)
  • Figure 24.13 Pharmaceutical Fill / Finish Manufacturing Market in Rest of Europe, till 2035 (USD Billion)
  • Figure 24.14 Pharmaceutical Fill / Finish Manufacturing Market in Asia-Pacific, till 2035 (USD Billion)
  • Figure 24.15 Pharmaceutical Fill / Finish Manufacturing Market in India, till 2035 (USD Billion)
  • Figure 24.16 Pharmaceutical Fill / Finish Manufacturing Market in Japan, till 2035 (USD Billion)
  • Figure 24.17 Pharmaceutical Fill / Finish Manufacturing Market in China, till 2035 (USD Billion)
  • Figure 24.18 Pharmaceutical Fill / Finish Manufacturing Market in Rest of Asia-Pacific, till 2035 (USD Billion)
  • Figure 24.19 Pharmaceutical Fill / Finish Manufacturing Market in Middle East and North Africa, till 2035 (USD Billion)
  • Figure 24.20 Pharmaceutical Fill / Finish Manufacturing Market in Latin America, till 2035 (USD Billion)
  • Figure 24.21 Pharmaceutical Fill / Finish Manufacturing Market in Rest of the World, till 2035 (USD Billion)
  • Figure 24.22 Penetration-Growth (P-G) Matrix: Geographical Regions
  • Figure 26.1 Conclusion: Small Molecules Fill / Finish Service Providers Landscape
  • Figure 26.2 Conclusion: Capacity Analysis
  • Figure 26.3 Conclusion: Market Forecast and Opportunity Analysis (I/II)
  • Figure 26.4 Conclusion: Market Forecast and Opportunity Analysis (II/II)